Literature DB >> 18437091

Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature.

Run Yu1, Nicholas N Nissen, Deepti Dhall, Anthony P Heaney.   

Abstract

We report a rare case of nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. The patient's clinical presentation, diagnosis, treatment, pancreas pathology, and follow-up are reviewed. A 60-year-old patient was incidentally found to harbor a pancreatic mass with markedly elevated glucagon levels but without glucagonoma syndrome. She was initially diagnosed with glucagonoma, and the tumor was resected. Pathological examination demonstrated that the tumor was a nonfunctioning islet cell tumor and revealed nesidioblastosis and hyperplasia of alpha cells and microglucagonoma in the apparently normal surgical margin. The patient still had high postoperative glucagons levels which were suppressed by somatostatin analog treatment. No pancreatic tumors recurred 36 months after surgery. This is the third case of alpha-cell nesidioblastosis reported in the English literature. Nesidioblastosis and hyperplasia of alpha cells should be considered in the differential diagnosis of hyperglucagonemia. Somatostatin analog may be used to suppress glucagon secretion in alpha-cell hyperplasia.

Entities:  

Mesh:

Year:  2008        PMID: 18437091     DOI: 10.1097/MPA.0b013e31815ceb23

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  18 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

Review 2.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 3.  The alpha-cell as target for type 2 diabetes therapy.

Authors:  Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 4.  Pathologic pancreatic endocrine cell hyperplasia.

Authors:  Debra Ouyang; Deepti Dhall; Run Yu
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

5.  Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome.

Authors:  Helen C Miller; Mark Kidd; Irvin M Modlin; Patrizia Cohen; Roberto Dina; Panagiotis Drymousis; Panagiotis Vlavianos; Günter Klöppel; Andrea Frilling
Journal:  World J Gastrointest Surg       Date:  2015-04-27

Review 6.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

7.  Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.

Authors:  Cuiqi Zhou; Deepti Dhall; Nicholas N Nissen; Chun-Rong Chen; Run Yu
Journal:  Pancreas       Date:  2009-11       Impact factor: 3.327

Review 8.  Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literature.

Authors:  Run Yu; Yun Zheng; Matthew B Lucas; Yun-Guang Tong
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

9.  Deleterious mutation V369M in the mouse GCGR gene causes abnormal plasma amino acid levels indicative of a possible liver-α-cell axis.

Authors:  Qiaofeng Liu; Guangyao Lin; Yan Chen; Wenbo Feng; Yingna Xu; Jianjun Lyu; Dehua Yang; Ming-Wei Wang
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

10.  Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.

Authors:  Run Yu; Deepti Dhall; Nicholas N Nissen; Cuiqi Zhou; Song-Guang Ren
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.